Why Bone Health Matters in CF
Cystic fibrosis (CF) is a multisystem disease best known for its impact on the lungs and pancreas. However, reduced bone mineral density (BMD) and fractures are increasingly recognized as major comorbidities that affect quality of life, mobility, and overall survival. Approximately 3040% of adolescents and up to 70% of adult CF patients have low BMD (a Tscore 1.0). Early identification and management are essential because once bone loss becomes severe, it is difficult to reverse.
Pathophysiology Why BMD Is Reduced
Multiple factors intersect to compromise bone health in CF:
- Vitamin D deficiency: Malabsorption caused by pancreatic insufficiency reduces intestinal absorption of fatsoluble vitamins.
- Chronic inflammation: Elevated cytokines (IL6, TNF) stimulate osteoclast activity.
- Glucocorticoid exposure: Frequent courses of oral or inhaled steroids for pulmonary exacerbations increase bone resorption and decrease formation.
- Physical inactivity: Reduced exercise limits mechanical loading, a key stimulus for bone formation.
- Delayed puberty and low body mass index (BMI): Hormonal deficits and reduced muscle mass lower the mechanical forces needed for bone accrual.
- CFTR dysfunction: Emerging evidence suggests that the CFTR protein may directly influence osteoblast differentiation.
Screening Recommendations
Guidelines from the Cystic Fibrosis Foundation (CFF) and the International Society for Clinical Densitometry (ISCD) recommend:
- Baseline dualenergy Xray absorptiometry (DXA) at age 1012 years.
- Repeating DXA every 12 years in children with risk factors (e.g., chronic steroids, BMI<5th percentile).
- For adults, DXA every 13 years, or sooner after a fracture or a change in therapy.
- Use of the Zscore (for patients <20years) and Tscore (20years) to interpret results.
Interpreting DXA Results
Key thresholds:
- Normal: Zscore1.0 (children) or Tscore1.0 (adults).
- Low bone mass (osteopenia): Zscore<1.0 but2.0, or Tscore between 1.0 and 2.5.
- Osteoporosis: Zscore<2.0 or Tscore2.5, or presence of a fragility fracture.
Management Strategies
1. Optimize Nutrition
Ensure adequate caloric intake to achieve a BMI at or above the 50th percentile.
Pancreatic enzyme replacement therapy (PERT) should be titrated to resolve steatorrhea and improve fatsoluble vitamin absorption.
Vitamin D: Target serum 25OH vitamin D30ng/mL. Highdose supplementation (e.g., 2,0004,000IU/day) may be needed, with periodic monitoring.
Calcium: Aim for 1,0001,300mg/day from diet and supplements as required.
2. Physical Activity
Weightbearing exercises (e.g., walking, jogging, resistance training) for at least 30minutes, 35 times per week, have been shown to increase BMD by 25% over 12months in CF cohorts.
3. Minimize Steroid Exposure
Use the lowest effective dose of oral glucocorticoids and consider steroidsparing agents (e.g., azithromycin, inhaled antibiotics). For chronic inhaled steroids, use the smallest particle size and appropriate dose.
4. Pharmacologic Therapy
When lifestyle and nutritional measures are insufficient, pharmacologic options are considered:
- Bisphosphonates: Alendronate or risedronate improve BMD by 37% over 2years. Intravenous zoledronic acid is an option for patients with severe disease or poor oral absorption.
- Denosumab: Offlabel use may be considered in adolescents with contraindications to bisphosphonates, though data are limited.
- Teriparatide: Reserved for severe osteoporosis with fractures; careful monitoring required.
All pharmacologic interventions should be accompanied by adequate calcium and vitamin D supplementation and reviewed annually.
Monitoring and Followup
Repeat DXA 12years after initiating therapy to assess response.
Track serum calcium, phosphate, alkaline phosphatase, and 25OH vitamin D every 612months.
Document any new fractures, changes in weight, or alterations in pulmonary regimen.
Special Considerations
Pregnancy
Pregnant women with CF need close monitoring of calcium and vitamin D, as fetal bone accretion can exacerbate maternal deficits. Bisphosphonates are contraindicated; focus on nutrition and safe physical activity.
Transplant Candidates
Prelungtransplant assessment includes DXA because posttransplant steroids can accelerate bone loss. Optimizing bone health before transplantation improves postoperative outcomes.
Key Takeaways
- Low BMD is a common, modifiable complication of cystic fibrosis.
- Regular DXA screening starting in early adolescence is essential.
- Nutrition, vitamin D, calcium, exercise, and judicious steroid use form the cornerstone of management.
- Bisphosphonates are the firstline pharmacologic therapy when lifestyle measures are insufficient.
- Individualized followup based on DXA trends, fracture history, and overall CF status optimizes bone health and improves longterm quality of life.
For further reading, consult the Cystic Fibrosis Foundation Bone Health Guidelines and the latest ISCD position statements.
